Dr. Reddy’s Teraleve ® 4mg and 8mg Fesoterodine Fumarate Prolonged-Release tablets have been available in the UK since their launch on 1st June 2022.
- Indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.
4mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number ‘4’.
8mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number ‘8’.
Tablets are packaged in aluminium-aluminium blisters in a carton with a PIL.
|Product Name||Strength||Pack Size||PIP Code||EAN No.||Legal Category|
|Teraleve® Fesoterodine Fumarate Prolonged-Release Tablets||4mg||28||125-6924||5036072008328||POM|
|Teraleve® Fesoterodine Fumarate Prolonged-Release Tablets||8mg||28||125-6932||5036072008311||POM|
Teraleve® Fesoterodine Fumarate Prolonged-Release tablets are available from your local wholesaler or by contacting Dr.Reddy’s on 01223 651475 or [email protected].
Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: http://www.medicines.org.uk. Prescribers are recommended to consult the summary of product characteristics before prescribing – SmPC.